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Abstract 
Background: The stimulator of interferon genes (STING) agonist (cGAMP) kills the cancer cells through the 
activation of the innate immune system. PC3 cells are high in BTK and low in STING. In this study, the effect 
of adding STING agonist, cGAMP, to docetaxel investigated. 
Materials and Methods: PC3 cells were treated with docetaxel, cGAMP, and a combination of the docetaxel 
and cGAMP. Cell toxicity was evaluated by MTT assay, and changes of STING, IRF3, BTK, and DDX41 genes’ 
expression were quantified by the real-time PCR. STING protein was also detected by Western blotting. 
Results: The IC50 of docetaxel was 31.1 nM, and cGAMP did not change it significantly but decreased 
docetaxel toxicity about 30%. Docetaxel increased IRF3, BTK, and DDX41 gene expression significantly, and 
STING protein about 5 folds. By adding cGAMP to docetaxel STING, IRF3, and BTK, expression decreased 
several folds. 
Conclusion: In this in vitro study, cGAMP potentiated docetaxel’s effects and alleviated it. 
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Introduction 
Since 2004, docetaxel has considered as first-line drug 
that use for treatment of metastatic castration-resistant 
prostate cancer (MCRPC). It is effective but little 
increases the survival. The disease relapses after 
docetaxel chemotherapy was seen and more treatment 
is required1, 2. 
DNA leakage from the host cell nucleus or 
mitochondria into the cytoplasm in pathological 
conditions like cancer activates the innate immune 
system. This activation occurs by binding to aberrant 
double-strand DNA (dsDNA) leaked from the host 
into the cytosol, cyclic GMP-AMP synthase (cGAS) 
makes a molecule called cyclic GMP-AMP (cGAMP)3, 
4. By attaching a cytosolic protein called the stimulator 
of interferon genes (STING), cGAMP starts an intrinsic 
immune response. STING, which is based in the 
cytosol, is an important receptor in the pathway for 
sensing cytosolic DNA5, 6. STING detects cGAMP and 
activates cytosolic kinase TKB1. Activated TKB1 
binds to IRF3 and phosphorylates this transcription 
factor. This transcription factor enters the nucleus and 
produces type I interferons7, 8. As a cytosol-based 
protein, STING plays a key role in stimulating the 
secretion of interferon. Therefore, the use of this protein 
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agonist (cGAMP) can activate immune response 
against cancer cells9-19. 
Many clinical trials have been conducted to improve 
the effectiveness of docetaxel in the treatment of 
MCRPC. Docetaxel has been tested in combination 
with various anticancer drugs, such as tyrosine kinase 
inhibitors (dasatinib), zebras (Zoledronic acid), and 
some experimental drugs such as atrasentan. 
However, clinical trials for the combination of 
docetaxel with other drugs failed20-22. Due to the lack 
of effective treatment for castration-resistant prostate 
cancer (CRPC), there is a pressing need for a new and 
effective therapeutic approach.  
There are many studies that used the combination of 
cGAMP with other anticancer drugs or cancer 
immunotherapy, and they found that these 
combinations potentiate the anticancer therapy23, 24. In 
a study by Tiejun Li on mice, it was observed that 
cGAMP improved the anti-tumor activity and clearly 
increased the in vivo toxicity of 5-FU. These results 
indicated that cGAMP is a new anti-tumor agent and 
has potential implications for cancer 
immunotherapy24. There has been no report on the 
effects of docetaxel with cGAMP on prostate cancer, 
and the current study was the first that may illustrate 
the synergistic effect of both drugs. Therefore, the 
importance of cGAMP in inhibiting the growth of 
cancer cells and the role of this agonist as an enhancer 
of the anti-cancer effect of docetaxel have been 
addressed in this in vitro study. 
Methods 
Cell culture: 
The PC3 cell line was purchased from the Iranian cell 
bank based at Iran’s Pasteur Institute. Cells were 
grown in RPMI containing 10% FBS in the presence 
of one cc penicillin/streptomycin (100 μg/ml) in a 
humidified incubator with 5% CO2 at 37 °C. When 
the cells reached the confluence, they were seeded and 
used for experiments in their growth phase. 
Cytotoxicity assay: 
Cell toxicity was measured using the method of MTT 
(3- [4,5 -dimethyl-2-thiazolyl] -2,5-diphenyl 
tetrazolium bromide), a yellow water-soluble salt. A 
total of 104 cells per well were seeded in a 96-well 
microplate. After 24 hours of incubation, cells were 
exposed to docetaxel for 48 hours at concentrations of 
7.5, 15, 25, 37 and 75 nM, cGAMP at concentrations of 
2.2, 4.4, 8.75, 17.5 and 35 μM, or the combination of 
35 μM of cGAMP and the above-mentioned docetaxel 
concentrations. After 48h incubation, the cell 
suspension was washed with PBS. Then, the prepared 
MTT solution (5mg MTT/1ml PBS) was added to each 
well. After 4 hours of incubation, formazan crystals 
were formed at 37 °C and 200 μl DMSO was added to 
each well in order to dissolve the purple crystals. After 
20 minutes of shaking, ELISA reader at 570 and 630 
nm, respectively measured the absorbance of the 
samples. The Graph Pad Prism software calculated the 
IC50 and the IC5 was selected in order to use the 
nontoxic concentrations of these two compounds to 
study the signaling pathway without interfering with the 
cell numbers.  
Gene expression study: 
PC3’s mRNAs were extracted using a Biobasic 
extraction kit after the cells were treated with docetaxel 
3.5 nm (IC5), cGAMP 1. 1 μM (IC5), or a combination 
of the two for 48 hours. The total concentration of 
mRNA and its quality were measured by the absorption 
ratio at 280/290 nm using a Nanodrop 
spectrophotometer (Allshang). Subsequently, the 
cDNA of the extracted RNA was synthesized using a 
kit (Takara Bio Inc., Japan) and 1 μg total RNA. Then, 
the cDNA was amplified by a real-time quantitative 
polymerase chain reaction (RT qPCR) using the 
SYBR® Green PCR (Ampliqon) master mix and 
primers designed at the NCBI site and synthesized by 
Bioneer Co, South Korea. β-actin primers as 






(Reverse: CACTGACATCAATGCTCGGC), BTK: 
(Forward: GCTCAAAAACGTAATCCGGTACA) 
(Reverse: GTCTTCCGGTGAGAACTCCC), and 
IRF3: (Forward: CGACCTTCCATCGTAGGAGTT) 
(Reverse: TGGGGCCAACACCATGTTA). 
The temperature profile in the real-time PCR reaction 
was an initial denaturation at 95 °C for 10 minutes and 
then included a three-step program for 40 cycles, which 
included 95°C for 15 seconds, 60°C for 30 seconds, and 
72°C for 25 seconds.  
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Western blot: 
Cells were lysed on ice by RIPA buffer (50 mM Tris 
HCl pH 7.5, 150 mM NaCl, 1% v/v Triton X100, 0.5% 
v/v sodium deoxycholate, 1 mM EDTA, 0.1% v/v 
sodium azide, 50 mM NaF, 0.1% sodium dodecyl 
sulfate [SDS], and 1 mM PMSF)21. The concentration 
of extracted proteins was measured by the Bradford 
method. Proteins were mixed with an equal volume of 
loading buffer (0.125 M Tris-HCl with pH 6.8, 4% of 
SDS, 20% glycine, and 10% of 2-mercaptoethanol). 
The mixture was heated to 96 °C for 5 minutes. The 
denatured proteins were separated on 10% SDS-
polyacrylamide gel by a Bio-Rad electrophoresis 
apparatus. The proteins were transferred from the gel 
to a polyvinylidene difluoride (PVDF) membrane by 
a Bio-Rad Mini Trans-Blot device. PVDF was placed 
overnight in a blocking solution (skim milk powder 
5% w/v in TBS-Tween buffer containing 10 mM Tris, 
100 mM NaCl, and 0.1 mM Tween-20 pH 7.4) at 4 °C. 
The membrane was then washed with a TBS-Tween 
buffer solution 3 times for 10 minutes. Then it was 
incubated for 3 hours in the original antibody (TMEM 
173) or in beta-actin as housekeeping. Then, the 
membrane was washed for 10 minutes 3 times with 
TBS-Tween buffer solution. Subsequently, it was 
incubated for 2 hours at room temperature with anti-
rabbit IgG secondary antibody. After washing the 
membrane 3 times with TBS-Tween buffer solution, 
the bands were detected in the darkroom by ECL. The 
density of the spots darkness was analyzed by ImageJ 
software so we reported the quantitative protein 
expression. 
Statistical analysis was performed by Graph pad Prism 
software for IC5 & IC50 calculations and REST 
software for gene expression analysis. 
Results 
Cytotoxicity study: 
The PC3 cells were treated with 2.2, 4.4, 8.75, 17.5, 
and 35 μM cGAMP for 48 hours, and their IC50 was 
11.46 μM (CI 95%: 7.0 – 18.8) (Figure 1B). The cells 
were treated with docetaxel at 7.5, 15, 25, 37, and 75 
nM for 48 hours, and the IC50 value was 31.1 nM (CI 
95%: 20.8 – 46.6) (Figure 1A). The IC50 of docetaxel 
at the above-mentioned concentrations in the presence 
of 35 μM cGAMP did not change significantly [33.8 
nM (CI 95%: 10.7 – 107.3)] (Figure 1A). The addition 
of cGAMP to the docetaxel caused an increase in the 
toxicity of the lower concentrations of docetaxel and 
reduced the toxicity of the higher concentrations of 
docetaxel, and the ceiling of the toxicity effects of the 
highest docetaxel concentration dropped from about 
90% to about 60% (Figure 1A). 
Gene expression:  
The PC3 cell line was treated with the IC5 
concentrations of docetaxel (3.75 nM), cGAMP (1.1 
μm), or their combination (cGAMP+docetaxel). All 
treatments reduced STING gene expression 
significantly, and in combination, they showed an 
additive effect (Figure 2). Docetaxel increased IRF3 
expression, but cGAMP decreased it significantly so 
cGAMP+docetaxel did not change it (Figure 2). 
DDX41 expression was increased by docetaxel 
treatment significantly, but cGAMP and 
cGAMP+docetaxel did not change it (Figure2). While 
cGAMP caused a significant reduction in BTK gene 
expression, other treatments did not show any change 
(Figure2). 
STING protein expression:  
In the western blot analysis, the beta-actin protein was 
used as a housekeeping protein, and STING protein 
expression with a molecular weight of 43 kDa was 
investigated by anti-STING antibody TMEM173. The 
results showed that STING protein expression 
increased in docetaxel treated cells (Figure 3). 
Discussion 
In this study, the effects of cGAMP, docetaxel and their 
combination on the growth of the prostate cancer cell 
line (PC3) investigated. While the IC50 of docetaxel was 
31.1 nM, the addition of cGAMP did not change it (33.8 
nM) significantly. While cGAMP reduced the effect of 
the highest toxic concentration of docetaxel by about 
30%, it potentiated the toxicity of its lower 
concentrations. While all treatments reduced the STING 
gene expression, its protein was higher than control in 
docetaxel treated cells. Except for STING, docetaxel 
treated cells showed an increase in IRF3, BTK, and 
DDX41 gene expression. In addition to STING, IRF3 
and BTK gene expression was suppressed several folds 
in cells treated by cGAMP. Therefore, docetaxel in 
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combination with cGAMP lost its positive inducible 
effect on IRF3, BTK, and DDX41 gene expression.  
STING is a transmembrane protein that attaches to the 
endoplasmic reticulum system and has 379 amino 
acids. It is also one of the most important DNA sensor 
that is directly stimulated by the cyclic di-nucleotides 
(CDNs) produced by DNA viruses and bacteria25-27. 
STING is actually a cytosolic DNA sensor. STING is 
activated by cGAMP produced by cGAS or by other 
DNA sensors DAI, IFI16, DDX41 after detection of 
 
 
Figure 1. Cell survival curve after treatment by 48 hours with 7.5, 15, 25, 37, and 75 nM docetaxel (A), 35, 17.5, 8.75, 4.375, and 2.187 μM 
cGAMP (B), and 7.5, 15, 25, 37, and 75 nM docetaxel in the presence of 35 μM cGAMP (A). 
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DNA in the cytoplasm28. The activation of STING 
triggers the production of INF1 and inflammatory 
cytokines. Interferons can directly activate the 
apoptosis in cancerous cell lines in vitro29. It is well-
known that dimerization, translocation, 
phosphorylation, and degradation are all STING 
activation and signaling hallmarks30, 31. 
Low concentration of c-di- GMP (0.01 nmol) 
provided strong effects as adjuvant therapy in 4T1 
cancer cells and at high concentrations (15-150 nmol) 
activate caspase 3 and killed tumor cells directly 32. In 
their study, Xiangshi et al. found that cGAMP 
injections into node mice, which had been 
subcutaneously implanted with human tumor cells 
line (MNK-45 human stomach, A549 human lung 
adenocarcinoma, luv colorectal carcinoma, SMV-7721 
hepatocellular carcinoma, PC3 prostate carcinoma, and 
SW1990 pancreatic carcinoma), had an acute toxicity 
effect, and it can be used as an anti-tumor drug. In that 
study, a serum concentration of 4 mg/ml was achieved 
with the administration of 10 mg/kg and 40 mg/kg 
cGAMP 33. High concentrations of c-di-GMP alone can 
reduce tumor growth, partly due to the expression of 
Caspase 3. Activating STING directly induces cell 
apoptosis and autophagy in cancer cells34, 35. In our 
study 2- 35 µM concentrations of cGAMP showed 
cytotoxicity, and its IC50 (11.46 µM) was about 500 
fold weaker than Xiangshi’s study, and boosted lower 
concentrations docetaxel cytotoxicity, but reduced high 
concentration docetaxel cytotoxicity effect (MTT 
 
 
Figure 2. STING, IRF3, BTK, and DDX41 gene expression in docetaxel, cGAMP, and docetaxel + cGAMP treated PC3 cell line. Gene 
expression related to the beta actin housekeeping gene was calculated by the REST software program. Statistical significance (* p < 0.05, 
** p < 0.01) was calculated to the control group. 
 
Docetaxel Enhances the Expression of STING Protein in PC3 Cells, and cGAMP Attenuates this Effect               Salimi et al. 
NBM 201 Novelty in Biomedicine 2020, 4, 196-204 
assay).  
CDNs increase the efficacy of several cancer 
treatments, including vaccines, CD47 blockage, and 
5-FU 36. Chemotherapy agents and radiotherapy can 
activate the cGAS-STING pathway and enhance the 
antitumor response of the immune system by inducing 
DNA damage. For example, cisplatin and etoposide 
cause cGAS STING induction through DNA damage 
and its cytosolic leakage 37.  
In a review article, Ng stated that there is strong 
evidence that DNA damage and leakage to the cytosol 
have profound effects on the innate immune response 
through the activation of the STING pathway. In vivo 
studies on mice have shown that STING agonists can 
potentiate anti-tumor treatment 38. In this study, we 
showed that STING protein translation, and IRF3, 
BTK, and DDX41 gene expression was significantly 
abolished after combining cGAMP to docetaxel. 
BTK, which mainly reported in the hematopoietic cells 
and B cell malignancies, is aberrantly highly expressed 
in the PC3 cell line and there is a correlation between 
its expression and prostate cancer grade39. Indeed, the 
kinase domain of BTK binds to DDX41 at the DEAD-
box domain, and phosphorylate it at Tyr414 boosting 
dsDNA attachment to DDX41 and this complex 
recruited and binds to the transmembrane region of 
STING and activates TBK/IRF3 pathway40. Our results 
showed that BTK, which is not involved in the cGAS-
STING pathway, was significantly reduced by cGAMP 
treatment. While DDX41 was not affected. 
The inhibitory effect of STING activation on 
tumorigenesis of prostate, colorectal, and melanoma 
 
 
Figure 3. (a) Photograph of STING protein assayed by Western blot method. (b) The chart represents STING protein expression compared 
to housekeeping beta-actin protein. 
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cancers has been proven11, 14, 17. STING expression 
has been reduced in CRC, melanoma, hepatic 
carcinoma (HCC), breast cancer, and gastric cancer 41. 
In a clinical study conducted by He et al., the 
expression of the STING protein was lower in prostate 
cancer cells than in the control group 41. An increase 
in STING expression in MCF-7 breast cancer was 
shown to reduce cell survival. Increasing the 
expression of STING in the MCF-7 cell line decreased 
survival due to increased NF-kB induction and 
caspase-8-mediated cell death 42. A defect in STING 
can help tumors escape from the immune system, and 
mutation or deletion in the STING coding genome can 
indicate a defect upstream of the STING pathway. In 
the study by He et al., the expression of STING in 
hepatocyte carcinoma was decreased compared with 
the control group. Lower STING expression is 
associated with higher disease stages and less patient 
survival. In a study by Song et al., STING expression 
was significantly lower in tumor tissue than in healthy 
tissue, and the severity of its decline was directly 
correlated to tumor mass, tumor penetration depth, 
lymphoid metastasis, TNM, and loss of survival 43. In 
in vitro studies, it has been observed that STING 
destruction results in the proliferation, invasion, and 
migration of cancer cells. Finally, STING can be 
considered as a potential factor in gastric cancer 
immunotherapy 43. In our study docetaxel increased 
STING level by 5 fold. Although its gene expression 
was decreased. STING turnover is controlled by 
numerous mechanisms, and this effect may be due to 
STING decay prevention.  
A study by Bose indicated that the STING/cGAMP 
pathway acts like a 2-edged sword in cancer; knowing 
the molecular details and adjusting the time and place 
in this pathway is very important. STING activators 
play a key role in this area. While the optimal cDNA 
concentration contributes to the diagnosis of the 
immune response to the tumor, the high level of 
cDNA after uncontrolled activation of STING can 
itself cause inflammation and carcinogenesis. 
Therefore, determining the optimal concentration of 
STING agonist in cancer has an effective therapeutic 
effect44. Several studies have suggested that STING 
activation can induce some tumor types45, 46. The 
complex role of STING may be related to the type of 
cell and the intensity of the downstream signals and 
the over-activation of STING may give the reverse 
result41. 
The regulation of STING expression has been studied. 
Although cGAS and STING expression is low in the 
basal state, their type I IFN product increases the 
expression of these two proteins greatly by a positive 
feedback47-49. In contrast, treatment with dsDNA and 
cGAMP has been reported to reduce STING protein 
expression in gastric cancer cells43, probably due to the 
STING negative feedback control50. Moreover, 2 ', 3'-
cGAMP affects AMPK and induces negative feedback 
on STING production through ULK150. ULK1 kinase, 
which phosphorylates STING in S366, as well as an E3 
ubiquitin ligase, TRIM30a, and RNF5, degrade STING 
and are considered as negative regulators of STING50-
52. The poly ubiquitination of STING attached to K48 
by RNF552 and TRIM30a51 degrades them by negative 
feedback control. Not only is STING stimulated by 2', 
3'-cGAMP, but it also plays a key role in facilitating 
clearance of 2', 3'-cGAMP 53. We reported in this study 
that, cGAMP not only reduced STING gene expression, 
but also reduced IRF3 and BTK gene expression too. 
Conclusion 
According to the current in vitro study, the addition of 
cGAMP to docetaxel deteriorated docetaxel 
cytotoxicity effects and reduced its effect on the STING 
activation pathway, which may be caused by the 
cGAMP negative feedback on STING pathway 
components. 
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